“Over the course of 2017, we implemented a series of significant changes that set the foundation for a new strategic direction for the company as a leader in pharmaceutical cannabinoids and spray technologies,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. Read More
The post Insys Therapeutic shares Plunge on Q4 miss appeared first on Dagga Magazine.